Main navigation english

Canadian Public Health Association

Program

Preliminary PROGRAM 

Download the Preliminary Program (PDF, 1.8 MB)

WEDNESDAY 8 December

Program is subject to change.

All times are Eastern Standard Time.

10:30 - 11:25

Co-developed learning activities

  • New and Future Technologies in Influenza Vaccines
    • The program is being co-developed with AMMI Canada and Seqirus to achieve scientific integrity, objectivity and balance.
  • Which Strategies Will Best Increase Durability of Vaccine Effectiveness and Cross-protection Against COVID Variants?
    • The program is being co-developed with Canadian Paediatric Society and Medicago to achieve scientific integrity, objectivity and balance.
11:25 - 11:30 Break
11:30 - 12:30 Plenary I - Risk Communications and debunking mis- and dis-information
12:30 - 12:45 Break

12:45 - 13:45

Concurrent Sessions 

  • Barriers and Opportunities to Increasing HPV Immunization for School-Aged Children in Canada
  • Oral Presentations
13:45 - 14:30 Exhibitor Networking Break
14:30 - 15:30

Concurrent Sessions

  • Canada’s Vaccine Injury Support Program
  • Immunization Frameworks in Canada: A nation-wide analysis of gaps in the “system”
  • Oral Presentations
15:30 - 15:45 Break
15:45 - 16:45 Plenary II - The future of mRNA vaccines and seasonal influenza
16:45 - 16:50 Break
16:50 - 17:45

Co-developed learning activities

  • Protection beyond Flu: What’s New for Influenza Vaccines among Adults 50+
    • The program is being co-developed with AMMI Canada and Sanofi Pasteur to achieve scientific integrity, objectivity and balance.
  • Passive Immunization Against COVID-19 and RSV: Pre-exposure Prophylaxis against intertwined Respiratory Diseases
    • The program is being co-developed with Canadian Paediatric Society and AstraZeneca to achieve scientific integrity, objectivity and balance.

THURSDAY 9 December

All times are Eastern Standard Time.

10:30 - 11:25

Co-developed learning activities

  • Evolution of mRNA vaccines from basic science to pandemic response to future prospects – the role in Canada’s immunization programs
    • The program is being co-developed with Canadian Paediatric Society and Moderna to achieve scientific integrity, objectivity and balance.
  • Cervical cancer elimination in Canada by 2040: Will we get there?
    • The program is being co-developed with Canadian Paediatric Society and Merck to achieve scientific integrity, objectivity and balance.
11:25 - 11:30 Break
11:30 - 12:30 Plenary III - Immunization and racism
12:30 - 12:45 Break

12:45 - 13:45

Concurrent Sessions 

  • It’s your move: Playing your CARDs to deal with stress-related responses during pediatric vaccinations
  • Oral Presentations
13:45 - 14:30 Exhibitor Networking Break
14:30 - 15:30

Concurrent Session

  • Vaccine supply chain transformation in the context of COVID-19: Lessons learned and looking forward
  • Creating a Digital Communication Channel to Vaccine-hesitant Pregnant and Parenting Canadians
  • Oral Presentations
15:30 - 15:45 Break
15:45 - 16:45 Plenary IV - From pandemic to endemic: The road forward
16:45 - 16:50 Break
16:50 - 17:45

Co-developed learning activities

  • Shifting our focus to increase adult vaccination coverage: a look at the pandemic’s impact on other infectious diseases
    • The program is being co-developed with AMMI Canada and GSK to achieve scientific integrity, objectivity and balance.
  • Pneumococcal Pneumonia and COVID-19 Pneumonia: Long-Term Outcomes
    • The program is being co-developed with AMMI Canada and Pfizer Canada to achieve scientific integrity, objectivity and balance.